文献速递胃肠动力与功能性疾病

罗马IV与罗马III肠易激综合征的症状稳定性比较

Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

本研究对自我报告患有肠易激综合征(IBS)的成人进行12个月纵向随访,同时应用罗马III和罗马IV标准。基线招募1375人,784人(57.0%)提供12个月数据。罗马IV标准下29.4%的IBS患者波动为其他功能性肠病,罗马III标准下为16.5%;罗马IV的IBS亚型变化比例(31.7%)亦高于罗马III(24.5%),开始新治疗未影响症状稳定性。

要点

  • 罗马IV标准诊断的IBS在12个月内波动为其他功能性肠病的比例为29.4%,高于罗马III的16.5%。
  • 仍符合罗马IV标准的IBS患者中亚型变化占31.7%,以混合型(IBS-M)最不稳定。
  • 开始新的IBS治疗未影响症状稳定性。

核心结论

  • 功能性肠病之间及IBS主要粪便亚型之间的波动在IBS患者中常见,且似乎不完全受治疗影响。
  • 罗马IV标准诊断的IBS似乎比罗马III标准诊断的IBS更不稳定。

研究设计与样本

  • 12个月纵向随访研究,从3个为IBS患者提供服务的组织招募自我报告患有IBS的成人。
  • 基线收集人口学、胃肠道症状、情绪和心理健康数据,12个月时收集胃肠道症状数据。
  • 基线和12个月时同时应用罗马III和罗马IV标准,并根据主要粪便性状或频率进行亚型分类。

主要发现

  • 基线招募1375人,784人(57.0%)在12个月时提供数据。
  • 基线时452人符合罗马IV标准,其中133人(29.4%)在12个月时波动为其他功能性肠病。
  • 仍符合罗马IV标准的319人(70.6%)中,101人(31.7%)IBS亚型发生变化,以IBS-M最不稳定。
  • 基线时631人符合罗马III标准并在12个月时应答,其中104人(16.5%)波动为其他功能性肠病。
  • 仍符合罗马III标准的527人(83.5%)中,129人(24.5%)IBS亚型发生变化,以IBS-M最稳定。

临床怎么用

  • 开始新的IBS治疗未影响罗马IV标准下的症状稳定性。
  • 开始新的IBS治疗未影响罗马III标准下的症状稳定性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Irritable bowel syndrome (IBS) is a chronic functional bowel disorder, which follows a relapsing and remitting course. Little is known about how evolving definitions of IBS or treatment for the condition affect symptom stability. We conducted a 12-month longitudinal follow-up study of individuals who self-identified as having IBS to examine these issues. METHODS: We collected demographic, gastrointestinal symptom, mood, and psychological health data at baseline, and gastrointestinal symptom data at 12 months, from adults who self-identified as having IBS, registered with 3 organizations providing services to people with IBS. We applied the Rome III and Rome IV criteria simultaneously at baseline and 12 months and subtyped participants according to predominant stool form or frequency. We examined stability of a diagnosis of IBS, and stability of IBS subtype, for the Rome IV and III criteria separately and examined the effect of commencing new therapy on fluctuation of symptoms. RESULTS: Of 1,375 individuals recruited at baseline, 784 (57.0%) provided data at 12 months. Of these, 452 met the Rome IV criteria for IBS at baseline, of whom 133 (29.4%) fluctuated to another functional bowel disorder at 12 months. In the remaining 319 (70.6%) who still met the Rome IV criteria for IBS, IBS subtype changed in 101 (31.7%) subjects, with IBS with mixed bowel habit (IBS-M) the least stable. Commencing a new treatment for IBS did not affect symptom stability. Among 631 who met the Rome III criteria at baseline responding at 12 months, 104 (16.5%) fluctuated to another functional bowel disorder. In the 527 (83.5%) who still met the Rome III criteria for IBS, IBS subtype fluctuated in 129 (24.5%), with IBS-M the most stable subtype. Again, commencing a new treatment for IBS did not affect symptom stability. DISCUSSION: Fluctuation between functional bowel disorders and predominant stool subtype is common in people with IBS and does not appear to be influenced solely by treatment. Rome IV IBS appears less stable than Rome III IBS.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Barberio B, Houghton LA, Yiannakou Y, et al. Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome. Am J Gastroenterol. 2021. PMID: 33009062. doi:10.14309/ajg.0000000000000946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。